Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era

Abstract

The field of cardio-oncology is rapidly evolving, moving beyond the traditional focus on anthracycline-induced cardiotoxicity and left ventricular ejection fraction (LVEF) decline. This review explores the expanding landscape of cardiotoxic therapies used in cancer treatment and the need for more comprehensive cardiac risk assessment. We discuss the emerging role of targeted therapies and immunotherapies in causing diverse forms of cardiotoxicity, often affecting different aspects of the heart compared to anthracyclines. The importance of early detection and proactive management strategies to ensure optimal patient outcomes in this growing population of cancer survivors is emphasized.

Introduction

For decades, cardiotoxicity associated with anthracycline chemotherapy has been a major concern in cancer treatment. Left ventricular ejection fraction (LVEF), a measure of heart pump function, has been the gold standard for monitoring this risk. However, the landscape of cancer therapies is changing, and cardio-oncology, the field focused on minimizing cardiac complications in cancer patients, is facing new challenges.

Beyond Anthracyclines: A Spectrum of Cardiotoxic Therapies

While anthracyclines remain a critical tool in certain cancers, newer therapeutic modalities are increasingly used. These include:

• Targeted therapies: These drugs specifically target cancer cells but can also have off-target effects on the heart, causing conditions like myocarditis (heart muscle inflammation) or arrhythmias (irregular heartbeats).

• Immunotherapies: These medications help the immune system fight cancer, but some can trigger immune-mediated myocarditis or vascular complications.

Shifting the Focus: Cardiotoxicity Beyond LVEF

While LVEF remains crucial, other aspects of cardiac dysfunction are becoming increasingly recognized. Newer cardiotoxic therapies can manifest as:

• Subtle declines in LVEF or asymptomatic changes in heart function.

• Diastolic dysfunction, where the heart has difficulty relaxing and filling with blood.

• Microvascular dysfunction, affects blood flow within the heart muscle.

Comprehensive Cardiac Risk Assessment in the Era of Cardio-Oncology

Given the diversity of cardiotoxic therapies, a more comprehensive approach to cardiac risk assessment is necessary. This may include:

• Detailed pre-treatment cardiac evaluation including medical history, physical examination, imaging (echocardiography), and biomarkers.

• Serial monitoring during and after treatment to detect subtle changes in cardiac function early on.

• Risk stratification is based on the specific cancer therapy and individual patient characteristics.

Conclusion

The field of cardio-oncology is adapting to the evolving landscape of cancer therapies. Moving beyond the traditional focus on anthracyclines and LVEF, a comprehensive approach is needed to identify cardiotoxic effects from various treatments and optimize patient care. Ongoing research and collaboration between oncologists and cardiologists are crucial to ensure improved long-term cardiovascular health in cancer survivors.

Read more such content on @ Hidoc Dr | Medical Learning App for Doctors